Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 9:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 2,289 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Open Label Extension Clear all
Terminated Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis

NCT05314517
View directory record Official record
Conditions
Sarcoidosis, Pulmonary
Interventions
Namilumab, Placebo
Drug
Lead sponsor
Kinevant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
24
States / cities
Birmingham, Alabama • Palo Alto, California • Valencia, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 29, 2026, 9:50 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis

NCT04877990
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
Deucravacitinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Shreveport, Louisiana • Wyoming, Michigan • Jackson, Mississippi + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 29, 2026, 9:50 PM EDT
Completed Phase 3 Interventional Results available

Evaluate Long-Term Safety and Efficacy WC3011 (Estradiol Vaginal Cream)

NCT01455597
View directory record Official record
Conditions
Vulvovaginal Atrophy
Interventions
WC3011 Estradiol Vaginal Cream
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
64
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 29, 2026, 9:50 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

NCT02938520
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), ABC/DTG/3TC STR - Tablet, DTG Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 29, 2026, 9:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study to Evaluate the Dose-Proportionality of Tramadol (ULTRAM) Extended-Release (ER) in Healthy Participants

NCT01800682
View directory record Official record
Conditions
Healthy
Interventions
Tramodol Extended-Release (ER)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 29, 2026, 9:50 PM EDT
Completed Phase 2 Interventional Results available

Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E

NCT01792115
View directory record Official record
Conditions
Fatty Liver
Interventions
Vitamin E 200 IU/d, Vitamin E 400 IU/d, Vitamin E 800 IU/d, Diet and Exercise
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 29, 2026, 9:50 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD

NCT04714359
View directory record Official record
Conditions
PTSD
Interventions
Midomafetamine HCl
Drug
Lead sponsor
Resilient Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Boulder, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 29, 2026, 9:50 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors

NCT02452424
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Gastrointestinal Stromal Tumor (GIST), Ovarian Cancer
Interventions
PLX3397, Pembrolizumab
Drug · Biological
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Oct 29, 2026, 9:50 PM EDT
Completed Phase 2 Interventional

An Extension of the TG1101-RMS201 Trial

NCT03381170
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Ublituximab
Biological
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
8
States / cities
Pasadena, California • Aurora, Colorado • Lexington, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 29, 2026, 9:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults

NCT07066722
View directory record Official record
Conditions
HIV Infections
Interventions
VH4524184, Itraconazole, Rifabutin, Phenytoin, Metformin, Digoxin
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 60 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 29, 2026, 9:50 PM EDT
Completed Phase 1Phase 2 Interventional

DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2

NCT03466320
View directory record Official record
Conditions
AML, MDS
Interventions
NKR-2
Biological
Lead sponsor
Celyad Oncology SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 29, 2026, 9:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants

NCT04371380
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir Tablets, Rilpivirine Tablets, Cabotegravir extended release suspension for injection (long-acting), Rilpivirine extended release suspension for injection (long-acting)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 29, 2026, 9:50 PM EDT
Active, not recruiting Phase 3 Interventional

Nipocalimab in Moderate to Severe Sjogren's Disease

NCT06741969
View directory record Official record
Conditions
Sjogrens Syndrome
Interventions
Nipocalimab, Placebo, Standard of care treatment
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
43
States / cities
Chula Vista, California • Fullerton, California • La Palma, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 29, 2026, 9:50 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

NCT03748641
View directory record Official record
Conditions
Castration-Resistant Prostatic Cancer
Interventions
Niraparib, Abiraterone Acetate, Prednisone, Placebo, New Formulation of Niraparib and Abiraterone Acetate (AA)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
765 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
47
States / cities
Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 29, 2026, 9:50 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe Ambulatory Impairment

NCT02731690
View directory record Official record
Conditions
Hereditary Inclusion Body Myopathy, Distal Myopathy With Rimmed Vacuoles, Distal Myopathy, Nonaka Type, GNE Myopathy, Quadriceps Sparing Myopathy, Inclusion Body Myopathy 2
Interventions
Aceneuramic Acid Extended-Release
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Orange, California • St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 29, 2026, 9:50 PM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

NCT04712097
View directory record Official record
Conditions
Relapsed or Refractory Follicular Lymphoma
Interventions
Mosunetuzumab, Lenalidomide, Rituximab, Tociluzumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
17
States / cities
Duarte, California • Atlanta, Georgia • Fort Wayne, Indiana + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 29, 2026, 9:50 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

NCT02932410
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan, Standard-of-care
Drug · Other
Lead sponsor
Actelion
Industry
Eligibility
1 Month to 17 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 29, 2026, 9:50 PM EDT
Completed Phase 3 Interventional Results available

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)

NCT03985982
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxin A, Placebo
Drug
Lead sponsor
Croma-Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 29, 2026, 9:50 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.

NCT00605280
View directory record Official record
Conditions
Macular Edema Associated With Diabetes Mellitus
Interventions
Standard of Care, Macugen
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
28
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 29, 2026, 9:50 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis

NCT02943447
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Cilofexor, Placebo to match cilofexor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
13
States / cities
Sacramento, California • Aurora, Colorado • Lakewood Rch, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 29, 2026, 9:50 PM EDT
Recruiting Phase 3 Interventional

Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)

NCT07608432
View directory record Official record
Conditions
Duchenne Muscular Dystrophy (DMD), Muscular Dystrophy, Duchenne, Muscular Dystrophy (DMD), DMD, Muscular Dystrophies, Muscular Dystrophy in Children, Muscular Dystrophy, Duchenne Type, Muscular Dystrophy, Duchenne and Becker Types, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Genetic Disease, Inborn, Genetic Disease, X-Linked, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neuromuscular Diseases (NMD)
Interventions
Zeleciment Rostudirsen (DYNE-251), Placebo
Drug
Lead sponsor
Dyne Therapeutics
Industry
Eligibility
4 Years to 18 Years · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Hillsborough, North Carolina
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 29, 2026, 9:50 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis

NCT01955733
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
BI 695500
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 82 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
29
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 29, 2026, 9:50 PM EDT
Terminated Phase 2 Interventional Results available

Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)

NCT02976038
View directory record Official record
Conditions
Primary Mitochondrial Disease
Interventions
elamipretide
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
16 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
San Diego, California • Boston, Massachusetts • Akron, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 29, 2026, 9:50 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome

NCT00107848
View directory record Official record
Conditions
Narcolepsy, Sleep Apnea, Obstructive
Interventions
Modafinil
Drug
Lead sponsor
Cephalon
Industry
Eligibility
6 Years to 16 Years
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
55
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 29, 2026, 9:50 PM EDT